Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...
Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, includin...
Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device....
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to...
BOSTON , June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launch...
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections....
Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Skechers (SKX), Walmart (WMT), Haemonetics (HAE), AZZ Inc. (AZZ) an...
